GlassScriptPhysician profile
Mandi Lahman
NPI 1629461009
$3,517.63
in general payments reported to CMS, 2019-2025
29 companies · $1,039 in 2025
The $1,039 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $307 · 2022: $561 · 2023: $818 · 2024: $792 · 2025: $1,039.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,649.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,649.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $553.04 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $377.28 | 2021-2025 | |
| Pfizer INC. | $370.20 | 2021-2025 | |
| Lilly USA, LLC | $306.62 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $255.72 | 2021-2025 | Evenity, Prolia, Repatha |
| Merck Sharp & Dohme LLC | $222.84 | 2021-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Glaxosmithkline, LLC. | $178.98 | 2021-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $150.24 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Abbott Laboratories | $146.65 | 2022-2025 | Freestyle Libre 3, Proclaim |
| Astellas Pharma US INC | $144.90 | 2023-2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.64 | 2021-2023 | Jardiance, Stiolto Respimat |
| Exact Sciences Corporation | $106.25 | 2023-2024 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $71.26 | 2023-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.65 | 2024-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $66.62 | 2022-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $55.33 | 2023-2025 | Camzyos, Eliquis |
| Phathom Pharmaceuticals, INC. | $53.79 | 2024-2025 | Voquezna |
| Daiichi Sankyo INC. | $39.56 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $36.38 | 2025 | Vowst |
| Esperion Therapeutics, INC. | $23.03 | 2023 | Nexletol |
| Novartis Pharmaceuticals Corporation | $21.32 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.07 | 2022 | |
| Biomarin Pharmaceutical INC. | $19.48 | 2024 | Voxzogo 1.2mg |
| Biogen, INC. | $19.15 | 2024 | Spinraza |
| Amarin Pharma, INC. | $18.35 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $18.00 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $15.50 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.60 | 2022 | |
| Eisai INC. | $12.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mandi Lahman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.